Malaysia's Duopharma to capitalize on growing SEA biosimilars market
HONG KONG Malaysia-based CCM Duopharma Biotech Bhd is positioning itself to capitalize on the growing biosimilars market in Southeast Asia (SEA), following the success of a phase III trial of its erythropoietin (EPO) biosimilar for kidney dialysis. The Kuala Lumpur-based company is set to commence registration of the drug and further strengthen its position in the Malaysian market.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST